Indivior PLC Overview
Pro stress-test →Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company is executing a strategic transformation to accelerate growth and profitability in 2026 through its Indivior Action Agenda.
Strategic Profile
Pro stress-test →The company completed Phase I of its transformation by growing U.S. SUBLOCADE net revenue, simplifying the organization and achieving expected annual non-GAAP operating expense savings of at least $150 million. Phase II, launched January 1, 2026, focuses on accelerating U.S. SUBLOCADE dispense unit growth and net revenue while immediately accelerating adjusted EBITDA and cash flow.
Competitive Landscape
Pro stress-test →Indivior operates in the OUD treatment pharmaceutical market competing against major pharma players offering buprenorphine and methadone formulations. Key competitors include Purdue Pharma (suboxone alternatives), Hikma Pharmaceuticals (generic buprenorphine), and emerging players in medication-assisted treatment (MAT). Indivior's SUBLOCADE (extended-release buprenorphine injection) differentiates through its once-monthly dosing convenience and clinical profile.
Industry Context
Indivior PLC operates in Specialty Pharmaceuticals - Opioid Use Disorder Treatment.
Key facts
Headquarters: Richmond, Virginia, United States · Revenue: $1.125-1.195B (2026 guidance)